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icodextrin-based dialysis solution. This protocol had to be discontinued
after six weeks because hyperosmolality developed due to extensive
absorption of glycerol. The CCPD was continued with glucose-based
solutions. At the age of 26, he experienced an unexplained episode of
abdominal pain, nausea, vomiting, and watery diarrhea for one week.
Two weeks later, this recurred and the patient was admitted to the
hospital. The dialysate cell count was 210/mm3; the dialysate culture
yielded Staphylococcus epidermidis. This peritonitis episode responded
well to treatment with vancomycin. Five weeks after discharge, rehospi-
talization was required because of the symptoms already noted.
On physical examination, the patient was not acutely ill and appeared
well hydrated. His temperature was 398C; his pulse was 112 beats/min
and regular, and his blood pressure was 140/80 mm Hg. The exit site
of the Tenckhoff catheter was not infected. Bowel sounds were sparse,
and abdominal tenderness was present in the left abdominal region.
The peritoneal effluent contained 250 cells/mm3, and Gram’s stain
showed gram-negative rods; the culture grew Citrobacter freundii. BloodCASE PRESENTATION investigations showed the following: creatinine, 1070 mmol/liter (12.1
A 26-year-old man was admitted to the hospital because of abdomi- mg/dl); urea, 17 mmol/liter; albumin, 47 g/liter; white blood cell count,
nal pain and vomiting. He had end-stage renal failure due to vesico- 9.2 3 109/liter; amylase, 27 U/liter (normal value , 160 U/liter). Treat-
ureteral reflux and frequent urinary tract infections. Hemodialysis had ment with ciprofloxacin intraperitoneally was started immediately after
been started at the age of 16. A left-sided nephrectomy was performed the results of the Gram’s stain became available. After three days, the
six months later, and a Tenckhoff catheter was implanted for continu- effluent cell number had decreased to 100/mm3, and the culture was
ous ambulatory peritoneal dialysis (CAPD). The CAPD, started one negative. However, signs of bowel obstruction developed; nasogastric
month after catheter implantation, proceeded uneventfully for two suction and total parenteral nutrition were started. One week after
and one-half years, except for one episode of peritonitis four months admission, a plasma amylase was 1300 U/liter, which reached a maximum
after the start. The peritonitis, caused by Staphylococcus epidermidis, value of 2000 U/liter over the following few days. The effluent cell count
responded well to antibiotic treatment. A right-sided nephrectomy was increased to 480/mm3, but cultures remained negative. A diagnosis of
performed at the age of 18. Continuous cycling peritoneal dialysis pancreatitis was made, and the following laboratory values were found:
(CCPD) was started for social reasons after 30 months of CAPD. The bilirubin, 70 mmol/liter; calcium, 2.58 mmol/liter; triglycerides, 1.71
patient alternated 3.86% glucose exchanges with 2.27% exchanges. A mmol/liter; glucose, 9 mmol/liter. An ultrasound examination showed
second peritonitis episode, this one caused by Enterococcus, occurred no distention of the gallbladder ducts, and endoscopic retrograde
after 27 months of CCPD. This episode also responded well to antibiotics. choledocho-pancreaticography could not demonstrate an obstructing
After five years of peritoneal dialysis, the patient reported using gallstone. A CT scan revealed a swollen pancreas and thickened bowel
3.86% glucose solutions almost exclusively, because he had noticed a walls but was not diagnostic for peritoneal sclerosis. Nasogastric suc-
decrease in his ultrafiltration capacity. During a standard four-hour tion, total parenteral nutrition, and ciprofloxacin intraperitoneally were
dwell, he absorbed 11 ml of a two-liter, 1.36% glucose solution. A continued. The daily dialysis prescription was changed to one exchange
cadaveric renal transplant was performed at the age of 22, but one of icodextrin, one of amino acids, and two of glycerol-based dialysate;
month later, the graft had to be removed because of rejection resistant in addition, heparin was given intraperitoneally. The signs of bowel
to treatment. The CCPD was resumed. Five months later the patient obstruction and pancreatitis had disappeared after two weeks, and oral
was admitted because of overhydration. A CT scan of the abdomen nutrition was restarted. The dialysate cell count decreased to normal
showed no signs of peritoneal sclerosis. Peritoneal dialysis was discon- values. Ciprofloxacin was discontinued after a total of three weeks.
tinued for five weeks, but this period of “peritoneal resting” had no Apart from a period of unexplained watery diarrhea that resolved
effect on ultrafiltration. The patient refused definitive transfer to hemo- spontaneously, the patient has been well for three months.
dialysis. At the age of 24, he participated in a trial on the effects of
non–glucose-containing dialysis solutions. He daily performed five
short exchanges with 2.5% glycerol and one long exchange with 7.5% DISCUSSION
Dr. Raymond T. Krediet (Associate Professor of Med-
Presentation of this Forum is made possible by grants from Merck and icine and Vice-Director, Division of Nephrology, Depart-
Co., Incorporated; Astra Pharmaceuticals; Hoechst Marion Roussel, ment of Medicine, Academic Medical Center, UniversityIncorporated; Dialysis Clinic, Incorporated; and R & D Laboratories,
of Amsterdam, Amsterdam, The Netherlands): The pa-Incorporated.
tient I presented today clearly demonstrates what you allKey words: peritoneal sclerosis, peritoneal transport, mesothelial cell
markers, aquaporin, CA 125. know—that long-term peritoneal dialysis can damage the
peritoneal membrane. Although the diagnosis of perito- 1999 by the International Society of Nephrology
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Fig. 1. Time course of renal replacement ther-
apy in the presented patient and the results of
the peritoneal membrane investigations. The
hatched areas represent the lowest part of the
normal range for 3.86% glucose-induced ul-
trafiltration [53] and for dialysate CA 125 [31].
The shaded areas for MTAC of creatinine,
glucose absorption, and the restriction coeffi-
cient for macromolecules represent the nor-
mal range of these parameters in stable CAPD
patients [100].
neal sclerosis could not be made with certainty, the severe patients who underwent catheter surgery for various rea-
sons. As peritoneal biopsies cannot be performed with-ultrafiltration failure and the prolonged period of bowel
obstruction make it likely that peritoneal sclerosis had out a concomitant reason for surgery, peritoneal histology
is not a tool that can be readily used in the managementdeveloped in this patient, who had been treated with peri-
toneal dialysis for 10 years. I selected this patient for of individual patients. This problem has evoked interest
in substances that are synthesized in peritoneal cells,discussion because we had longitudinal data on the status
and function of his peritoneal membrane, and also because especially mesothelial cells, that can be measured in peri-
toneal effluent [2, 3]. These substances, markers of peri-several attempts were made to reverse his membrane fail-
ure. The clinical course and the results of the peritoneal toneal membrane function, thus serve as surrogates for
peritoneal histology.membrane investigations are summarized in Figure 1.
The peritoneal membrane in patients treated by peri- Studies in isolated mesenteries [4] and in rats [5] have
shown that the mesothelial layer probably is not an im-toneal dialysis traditionally is investigated by study of
the transport of low-molecular-weight solutes [1] and by portant barrier to the transport of solutes and therefore
also not an osmotic barrier [5]. The vascular wall is likelyhistologic examination of peritoneal biopsy specimens
taken during removal or insertion of the peritoneal cath- the most important barrier to solute transport during
peritoneal dialysis, although the contribution of intersti-eter. Our knowledge of the morphology of the perito-
neum during chronic peritoneal dialysis is mainly com- tial tissue to such transport is not known. Therefore, the
following simplification can be made: Peritoneal trans-posed of a compilation of findings obtained in different
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port studies mainly reflect the vascular integrity of the mainly caused by variations in the vascular surface area,
and thus the number of available pores. A rise in theperitoneal membrane, whereas effluent concentrations
MTAC indicates an increase in the number of availableof substances synthesized in peritoneal cells, that is, the
pores and vice versa. Consequently, the MTAC of a low-markers, provide information on the health of peritoneal
molecular-weight solute, such as creatinine, provides in-tissues, especially the mesothelium.
formation on the peritoneal vascular surface area. TheAfter reviewing the basic concepts of peritoneal trans-
RC of macromolecules represents the size selectivity,port and the literature data on effluent markers of perito-
that is, the intrinsic permeability that is dependent on theneal tissues, I will focus especially on alterations in trans-
radius of the large pores; a low permeability is reflected inport and markers that can occur in long-term peritoneal
a high RC.dialysis, the etiology of these membrane changes, and
The absorption of glucose during a four-hour dwelloptions for prevention and treatment. The critical mes-
averages 60% to 70%, regardless of the concentrationsage I want to convey in this forum is the importance of
used [10]. The observation that glucose is an effectivecontinuous exposure to extremely high dialysate glucose
osmotic agent, despite this high level of absorption, cannotconcentrations in the pathogenesis of these alterations.
be explained by the two-pore theory. On the basis ofIdentification of patients at risk can be improved by
computer simulations, Rippe and colleagues have hypoth-regular monitoring of the peritoneal membrane status.
esized the existence of “ultrasmall” pores (radius ,5 A˚)This monitoring requires a standardized analysis, not
that allow the transport of water, but not of electrolytesonly of solute transport, but also of ultrafiltration and
and other solutes [11]. We subsequently demonstratedperitoneal tissue markers.
the presence of the water channel aquaporin-1 in the
peritoneal microvasculature of CAPD patients [12].Peritoneal transport
Therefore, this transcellular protein might actually beDiffusion of solutes from peritoneal capillaries to the
the ultrasmall pore. Aquaporin-mediated water trans-dialysis fluid is size selective and is generally considered
port explains the decrease of the dialysate concentrationto occur through a system of pores, mainly small pores
of sodium that occurs during the initial phase of a 3.86%
with radii of 40 A˚ to 50 A˚ [6]. Low-molecular-weight glucose exchange [13], reflecting the transport of water
solutes such as urea, creatinine, and glucose diffuse from the circulation into the peritoneal cavity without
through these pores. In addition to the system of small transport of sodium. Therefore, the dialysate/plasma ra-
pores, a small number of large pores (less than 0.1% of tio (D/P) of sodium at 60 minutes during a 3.86% glucose
the total number) permit the transport of macromole- exchange can be used as a reasonable indication of the
cules [7]. These small and large pores are responsible magnitude of aquaporin-mediated water transport [14].
for the size selectivity of peritoneal solute transport. This Computer simulations also hypothesized that about one
size selectivity can be expressed as the restriction coeffi- half of the volume filtered across the capillary wall during
cient (RC) [8]. The RC is the exponent in the power peritoneal dialysis occurs through water channels [11,
relation that exists between mass transfer area coeffi- 15]. We confirmed this prediction in a cross-sectional
cients (MTAC) of various solutes and their free diffusion analysis of 10 patients but found large differences among
coefficients in water (Dw): these patients [16].
Summarizing these data, it appears that peritoneal trans-MTAC 5 constant 3 DwRC
port studies using 3.86% glucose solutions during standard
This equation can be rewritten as: dwells provide extensive information. The MTAC of
creatinine reflects the peritoneal vascular surface area,logMTAC 5 RC log Dw 1 log constant
and the D/P Na1 at 60 minutes reflects aquaporin-medi-
Therefore, RC is the slope of the linear relationship be- ated water transport. When clearances of serum proteins
tween the MTAC of various solutes and their free diffu- such as b2-microglobulin, albumin, IgG, and a2-macro-
sion coefficients in water when plotted on a double loga- globulin are also determined, the calculated RC on the
rithmic scale. It follows from these equations that the clearances of these proteins can give an indication of the
relationship between the MTAC of solutes and their Dw size selectivity or permeability of the peritoneal mem-
is linear when RC 5 1.0. In this situation, the peritoneum brane.
is not a size-selective barrier to solute transport; the
Markers in peritoneal effluentmagnitude of transport is determined only by the avail-
able surface area, which is highly dependent on the num- A number of locally produced or released substances
ber of perfused peritoneal capillaries, and thus the num- are present in peritoneal effluent. Among these are vari-
ber of pores. In a recent cross-sectional study, we found ous cytokines [3], but also phospholipids, glycoproteins,
that the RC of low-molecular-weight solutes averaged glycosaminoglycans, and proteins involved in coagula-
1.2; that of serum proteins always exceeded 2.0 [9]. tion and fibrinolysis [2, 3]. The phospholipids in drained
dialysate largely consist of phosphatidylcholine (55% toTherefore, variations in the MTAC of a small solute are
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85%) [17–19]. They are mainly, but not exclusively, syn- The peritoneal membrane in long-term
thesized by mesothelial cells [20]. Glycosaminoglycans, peritoneal dialysis
consisting of hyaluronan and proteoglycans, also can be Replacement of the mesothelium by an acellular rind
detected in peritoneal effluent. Again, mesothelial cells of collagen is the most frequently described peritoneal
are the predominant source [21–23], but secretion of morphologic abnormality in long-term peritoneal dial-
glycosaminoglycans by other cells present in peritoneal ysis patients [37]. This abnormality might or might not
tissues, such as fibroblasts, is also possible. For instance, be accompanied by interstitial fibrosis. Marked vascular
synovial fibroblasts secrete hyaluronan [24]. abnormalities also can be present. The number of perito-
Cancer antigen 125 (CA 125) is a 220,000 Da glycopro- neal microvessels is markedly increased (unpublished
tein; its serum concentration is used as a marker for data). At the ultrastructural level, diabetiform reduplica-
ovarian neoplasms [25]. The antigen is also present in tions of the basement membrane of peritoneal capillaries
mesothelial cells [26]. Mesothelial cells in effluent of have been described [38–40]. The media of the vascular
peritoneal dialysis patients express CA 125 [27]. Cul- wall often show signs of fibrosis and hyalinization with
tured human peritoneal mesothelial cells obtained from deposition of collagen IV in the extracellular matrix,
omental tissue or the effluent of peritoneal dialysis pa- similar to the situation in diabetic microangiopathy [41].
tients released CA 125 exponentially during the first Collagen III and VI have mainly been described in areas
seven days of culture [28]. After cellular confluence was with interstitial fibrosis [41], which can progress to perito-
reached on day 8, the increase in the supernatant concen- neal sclerosis [42]. The sclerosing process can involve
tration became linear, indicating a constant production the bowel wall and lead to mural fibrosis [43]. In its
in time. This production rate could not be stimulated most extreme form, the fibrotic process causes sclerosing
with cytokines [28]. Higher CA 125 concentrations were encapsulating peritonitis, in which the bowel loops are
found when larger numbers of mesothelial cells were entrapped in a dense cocoon of fibrous tissue [44].
brought into culture [27]. These findings suggest that Ultrafiltration failure is the most frequent functional
CA 125 concentrations in peritoneal effluent represent
transport abnormality in long-term peritoneal dialysis.
mesothelial cell mass or mesothelial cell turnover in sta-
Inadequate dialysis, due to either insufficient controlble peritoneal dialysis patients. This contention is further
of uremia or to poor ultrafiltration, was the reason forsupported by the following: (1) A positive relationship
discontinuation in, on average, 16% of all peritonealis present between the number of mesothelial cells and
dialysis patients transferred to hemodialysis in three ma-the CA 125 concentration in peritoneal effluent [27, 28].
jor studies over the last decade [45–47]. This percentage(2) CA 125 is not synthesized by other cells present in
might be an underestimation, because the causes forperitoneal tissues or by leukocytes [29]. (3) The concen-
transfer were not analyzed with respect to the durationtration of CA 125 in the dialysate increased linearly
of peritoneal dialysis, and the duration of follow-up oftenduring a four-hour dwell, irrespective of the glucose con-
was less than four years [45, 46]. It might explain whycentration or osmolality of the dialysis fluid used [30].
loss of ultrafiltration was the main reason for discontinu-This increase cannot be explained by transport from the
ation of peritoneal dialysis in patients (51%) from Japancirculation, in view of the high molecular weight of this
who had been treated for six years or more [48].glycoprotein [27]. No relationship has been found be-
The prevalence of ultrafiltration failure depends ontween dialysate CA 125 concentrations and the perme-
the definition used and on the case mix of the studiedability characteristics of the peritoneum [31]. This finding
population, that is, the mean duration of peritoneal dial-confirms the observation from physiologic studies that
ysis and the percentage of long-term patients. Clinicalthe mesothelium is not an important transport barrier
definitions are subject to observer bias and depend onduring peritoneal dialysis.
the compliance of the patients. Objective informationDuring the processing of procollagen I and III to colla-
can be obtained using peritoneal function tests. Datagen, procollagen I-C-terminal peptide (PICP) and pro-
acquired with the peritoneal equilibration test suggestcollagen III-N-terminal peptide (PIIINP) are split off
that net ultrafiltration of less than 100 ml after four hours[32]. Serum concentrations of PIIINP have been used to
using two liters of 2.27% glucose dialysate is consideredassess the degree of hepatic fibrosis in patients with liver
abnormal [1, 49, 50]. Using two liters of 3.86% glucosedisease [33], and high levels of PIIINP are present in
dialysate, ultrafiltration of less than 400 ml after fourbronchoalveolar lavage fluids of patients with pulmonary
hours (roughly corresponding with 1.5 liter/day) is con-fibrosis [34]. More pertinent to our discussion today, the
sistent with ultrafiltration failure [9, 13, 51]. Recent com-concentrations of the procollagen peptides in dialysate
puter simulations suggest that the most sensitive methodeffluent exceed their serum concentrations on most occa-
for investigating ultrafiltration is with 3.86% glucose-sions [35, 36]. This finding suggests that dialysate concen-
based dialysate [52]. A cross-sectional study reported atrations of PICP and PIIINP could be used as markers
of collagen synthesis in the peritoneum. prevalence of ultrafiltration failure (defined by clinical
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criteria) of 6% [13]. Ultrafiltration failure increased from found in another investigation [67]. We also were unable
to demonstrate a decrease in the dialysate phospholipid3% after one year on CAPD to 31% after six years
[13]. Using the peritoneal equilibration test with 2.27% concentration during longitudinal follow-up [68]. In the
same study, the duration of CAPD had no effect onglucose dialysate, a prevalence of 14% has been found
[50]. Using 3.86% glucose, we recently found a value of dialysate hyaluronan levels [68]. In contrast, the duration
of CAPD clearly affected dialysate CA 125 concentra-23% in our patients in whom the duration of peritoneal
dialysis ranged from 0.3 to 178 months, median 19 months tions: Either high or low values could be present during
the first few years of treatment, but in long-term patients,[53]. In an ongoing multicenter study in unselected pa-
tients treated for more than four years, the prevalence only low values were found [31]. These data have been
confirmed during longitudinal follow-up [30, 68]. Also,of ultrafiltration failure was 38% (unpublished data).
Only a few longitudinal studies have been published low concentrations of CA 125 have been found in pa-
tients with peritoneal sclerosis [69]. Markedly elevatedwith more than 10 patients treated with lactate-buffered
dialysate and followed for more than three years [54–57]. dialysate levels of PIIINP and PICP have been described
in one patient with peritoneal sclerosis [35], but thisIn those studies in which standardized dwells were em-
ployed [56, 57], a decrease in ultrafiltration with time observation could not be confirmed in most other pa-
tients with this complication [69].on CAPD was reported, sometimes related to frequent
episodes of peritonitis, but also occurring in patients with
The impact of mesothelial cell loss ona low peritonitis incidence. Loss of ultrafiltration in these
local host defensestudies was mainly associated with increased transport
of low-molecular-weight solutes [56, 57], suggesting the Cultured mesothelial cells can secrete various cyto-
kines and chemokines [70] and also can ingest bacteriapresence of a large vascular peritoneal surface area. Also,
impaired aquaporin-mediated water transport can cause [71]. Patients on CAPD who had a high incidence of
peritonitis had fewer mesothelial cells in their night efflu-ultrafiltration failure in some long-term CAPD patients
[58]. We found a contribution of impaired aquaporin- ent than did patients with a lower incidence of peritonitis
[72]. Although a negative correlation between dialysatemediated water transport to ultrafiltration failure in about
one third of the patients with this complication [53] and CA 125 concentration and overall peritonitis incidence
was weak [68] and not reproducible [31], these data sug-obtained evidence that channel-mediated water transport
decreased with the duration of CAPD [16]. Ultrafiltration gest that the mesothelium is involved in the local host
defense during peritoneal dialysis. If so, impairment offailure is the most frequent transport abnormality in
patients with peritoneal sclerosis [59]. It can be associated host defense could be expected in long-term peritoneal
dialysis, especially in patients with peritoneal sclerosis.with either high or low solute transport rates [60]. In a
case-control study, patients with peritoneal sclerosis had At present, no study points to a higher incidence of
peritonitis in long-term patients than in those on perito-lower ultrafiltration rates and greater MTACs of creati-
nine than did a control group matched for the duration of neal dialysis for a shorter duration. However, data pre-
sented at the 16th Annual Conference on PeritonealCAPD [61]. Also, impaired aquaporin-mediated water
transport can contribute to ultrafiltration failure in this Dialysis (1996, unpublished data) showed that peritonitis
was an important reason for drop-out in peritoneal dial-condition [62].
The increase in the transport of low-molecular-weight ysis patients who had been treated for at least eight
years, although the overall peritonitis incidence in thesesolutes with the duration of peritoneal dialysis corre-
sponds with the large number of peritoneal microvessels patients was lower than that in the total peritoneal dial-
ysis population. This observation suggests a higher fre-present in peritoneal tissues of long-term patients. No
effect of the duration of CAPD was found on the RC quency of complicated, nonresolving peritonitis. In our
peritoneal sclerosis study, refractory or prolonged infec-for low-molecular-weight solutes in 108 patients [63].
These observations suggest an increase in the number tious peritonitis often preceded the diagnosis of perito-
neal sclerosis [61]. Furthermore, 4 of the 16 patients hadof small pores without a change in their radii. The RC
for macromolecules showed no consistent trend during more than one peritonitis episode with an initial dialysate
cell count below 100/mm3. These factors suggest im-the first two years of CAPD [64], but higher values were
present in long-term CAPD, both in a case-control study paired or delayed chemotaxis [73]. These scarce in vivo
data support the importance of the mesothelium in the[65] and during longitudinal follow-up [63]. This in-
creased size selectivity might be caused by a reduction local host defense.
in the large pore radius or by alterations in the interstitial
Etiology of the structural and functional alterations intissue.
the peritoneumA decrease in the phospholipid content of peritoneal
effluent with time on peritoneal dialysis has been re- Recurrent peritonitis has been implicated as a major
cause of the morphologic alterations [37] and of the trans-ported in two cross-sectional studies [18, 66] but was not
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port changes that can be found in long-term peritoneal [61, 89]. The incidence ranged from 0.0 to 4.3 per 1,000
patient years in a multicenter study from Japan [90]. Indialysis patients [56, 57]. Besides the well-known contri-
butions of acetate-based dialysis fluids [74] and chlorhex- patients treated for more than eight years, the prevalence
of peritoneal sclerosis rose to 19.4% [89]. It is unlikelyidine [75] in the genesis of peritoneal sclerosis, frequent
episodes of peritonitis, especially those caused by Staph- that the incidence of microbial peritonitis can be reduced
further than that currently achieved. Therefore, otherylococcus aureus [44], Pseudomonas aeruginosa, and fungi
[76], have been implicated. However, in more recent preventive methods must be investigated. Both tempo-
rary discontinuation of peritoneal dialysis (peritonealstudies, no relationship between peritoneal sclerosis and
the incidence of peritonitis could be found [61, 77, 78]. resting) and the reduction or avoidance of exposure to
hypertonic glucose solutions or glucose degradationThe relationship between the duration of peritoneal
dialysis and the occurrence of the peritoneal membrane products are interesting possibilities. Selgas’ group has
used peritoneal resting for four weeks in patients withalterations suggests that the continuous exposure to un-
physiologic dialysis fluids is an important pathogenetic ultrafiltration failure [91, 92]. This approach increased
ultrafiltration from 500 ml/24 hrs to 800 ml/24 hrs; thefactor. The commonly used fluids are not very biocom-
patible because of their low pH (5.5), type of buffer increase was accompanied by a decrease of the MTAC
of creatinine from 16.7 ml/min to 13.6 ml/min [92]. In(lactate), glucose concentration (75–200 mmol/liter), and
hypertonicity (osmolarity, 334–486 mOsm/liter). They a preliminary study from the United States, peritoneal
resting was not effective in two patients with peritonealalso contain aldehydes due to heat sterilization of the
fluids [79]. Studies with cultured mesothelial cells have sclerosis, but it decreased D/P ratios for creatinine and
increased dialysate CA 125 concentrations in two othersshown that both glucose and the combination of lactate
and a low pH are toxic [80, 81]. In vivo the low pH who had ultrafiltration failure [93]. Peritoneal resting
also has been associated with a decrease in dialysate CAmight be less important than lactate, because pH values
exceeding 7.0 are reached as soon as 10 minutes after 125, however [30].
Reducing the exposure of the peritoneal membrane toinstillation of the dialysate [82]. Indeed, glucose was
more toxic to mesothelial cells in a chronic animal model glucose or glucose degradation products is an emerging
method. A dialysis solution with a reduced concentrationthan were low pH, lactate, or hyperosmolality [83, 84].
Besides, glucose passes the mesothelium easily, exposing of aldehydes increased dialysate CA 125 concentrations
in a preliminary study [94]. Alternative osmotic agentsall peritoneal tissues to extremely high glucose concen-
trations. High glucose concentrations might not only that can replace glucose are glycerol, icodextrin (a glu-
cose polymer), and amino acids. Of these, only glycerolcause loss of mesothelium, but also the aforementioned
diabetiform vascular changes with deposition of collagen can be given four times a day. Lameire’s group has long-
term clinical experience, although in a limited numberIV [38–41]. These alterations might be caused by the for-
mation of advanced glycosylation end products (AGEs). of patients [95]. They found that glycerol was generally
well tolerated and was associated with stable clinical andNonenzymatic glycosylation is supported by the presence
of high concentrations of glycated albumin [85] and IgG biochemical control. No signs of hemolysis or hepatotox-
icity were found, but the development of a hyperosmolar[86] in the peritoneal effluent of CAPD patients and by
the demonstration of AGEs in peritoneal tissue of a syndrome due to high glycerol absorption rates was a
potential hazard. Amino acids and icodextrin-based solu-nondiabetic CAPD patient as soon as three months after
the start of CAPD [87]. In a recent study, accumulation tions can only be given once daily in the commonly used
concentrations, because of the nitrogen load and theof AGEs in peritoneal vascular walls was proportional
to the duration of CAPD [88]. Furthermore, patients accumulation of maltose in the extracellular volume. Ico-
dextrin was found to be safe in a six-month randomizedwith peritoneal sclerosis had a greater cumulative glu-
cose exposure than did controls matched for the duration study [96] and also after treatment for more than two
years [97]. Glucose polymers are attractive because theyof CAPD [61]. Although the evidence for an important
contribution of glucose in the pathogenesis of the perito- are not hypertonic, exert their effect by colloid osmosis,
and are taken up from the peritoneal cavity to a limitedneal membrane alterations is still circumstantial, the cur-
rently available data all point in the same direction; that extent, mainly by absorption into the lymphatic system.
They are therefore especially useful in patients with ul-is, glucose likely is the culprit.
trafiltration failure due to a large vascular peritoneal
Preserving the integrity of the peritoneal membrane surface area. In this situation, a large area is available
for fluid transport by colloid osmosis. Indeed, we haveThe abandoning of acetate as buffer substance in peri-
toneal dialysis fluids and chlorhexidine as disinfectant found such a favorable response [16, 98]; patients with
poor ultrafiltration on glucose-based dialysis solutionsduring the connection procedure has not led to the disap-
pearance of peritoneal sclerosis. Two recent studies have caused by rapid absorption of the osmotic agent second-
ary to a large surface area had marked ultrafiltration onreported incidences of 3.5 and 4.2 per 1,000 patient years
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icodextrin [98]. We treated nine patients who had severe peritoneal membrane can fail in the absence of frequent
or severe episodes of peritonitis. The last two episodesultrafiltration failure with a combination of glycerol- and
icodextrin-based solutions and found some improvement were remarkable because of the low cell count in the
effluent. As I said earlier, this finding might indicatein ultrafiltration and dialysate CA 125 concentrations
([99] and unpublished data). However, more studies on reduced release of chemotactic factors by the mesothe-
lium. The cause of the acute pancreatitis episode has notthis subject are required before final conclusions can be
drawn. been elucidated, but the combination of peritonitis and
pancreatitis has been described in the literature [101–Let me summarize the available evidence. It appears
that, for the preservation of the peritoneal membrane, 103]. Two attempts were made to reverse the peritoneal
abnormalities in this patient. The first was a five-weekextensive exposure to 3.86% glucose solutions should be
avoided as much as possible. Especially when a patient period of peritoneal resting, which had no effect on ultra-
filtration measured with 1.36% glucose dialysate. Theneeds 3.86% glucose to obtain ultrafiltration during the
once-a-day long dwell, this solution can better be re- second intervention was a trial with nonglucose dialysis
solutions. This maneuver increased ultrafiltration, mea-placed by 7.5% icodextrin. Furthermore, regular moni-
toring of the peritoneal membrane should be performed. sured with 3.86% glucose, from 89 ml/4 hrs to 131 ml/4
hrs, and dialysate CA 125 concentration from 1.09 U/mlThe widely used peritoneal equilibration test provides
insufficient information in its present form because only to 1.58 U/ml after a treatment period of six weeks. Based
on our hypotheses, we felt that this marginal improve-low-molecular-weight solutes are measured [1]. These
solutions reflect only the vascular surface area. The test ment justified another attempt with nonglucose solutions
in a situation in which acute discontinuation of peritonealcan be made more sensitive by using 3.86% glucose in-
stead of 2.27% [52] and by calculating MTACs in addi- dialysis almost certainly would have led to persistent
bowel obstruction. The results will have to be awaited.tion to D/P ratios [100]. Determination of the D/P ratio
of Na1 at 60 minutes gives additional information on
aquaporin-mediated water transport. The dialysate con-
QUESTIONS AND ANSWERS
centration of CA 125 after four hours should be mea-
Dr. Nicolaos E. Madias (Chief, Division of Nephrol-sured as a marker of mesothelial cell mass. A one-month
ogy, New England Medical Center, Boston, Massachu-peritoneal rest can be tried in patients with a documented
setts, USA): Could you give some more information ondecrease in ultrafiltration and CA 125 concentrations,
the epidemiology of peritoneal membrane failure, espe-but the effect should be monitored using the test I de-
cially whether the primary disease of the patient, forscribed. Apart from these direct practical consequences,
example, diabetes or vascular disease, affects the fre-more biocompatible solutions for peritoneal dialysis
quency of the disorder?should be developed using mixtures of various osmotic
Dr. Krediet: In our own series of 16 patients withagents in low concentrations. Such an approach will re-
peritoneal sclerosis, one had diabetes mellitus, one he-duce the possible toxicity of each of them.
molytic–uremic syndrome, one systemic lupus erythema-
Discussion of the presented case tosus, and one hypertensive nephropathy [61]. The other
12 all had renal failure due to a primary renal disease.The patient well demonstrates the ultrafiltration fail-
This distribution of underlying renal diseases is not es-ure that can occur during long-term peritoneal dialysis.
sentially different from that of all patients starting renalUltrafiltration failure was clearly associated with high
replacement therapy in Europe [104]. Also, an oldersolute transport rates pointing to a large vascular surface
survey from the Registry of the European Renal Associ-area. The absorption of glucose did not exceed the nor-
ation reported no overrepresentation of patients withmal range, probably because this range is so wide in
diabetes mellitus (13%), another multisystem diseaseperitoneal dialysis patients. With the exception of the
(4%), or renal vascular disease (2%) [77]. One of thelast measurement, the RC to macromolecules always
explanations for the lack of overrepresentation of dia-exceeded the normal range with a slight tendency to
betic patients might be the shorter survival on peritonealincrease during follow-up; this pattern is in accordance
dialysis when compared with that in nondiabetic patientswith the findings in our peritoneal dialysis population as
[105, 106]. An interesting point is whether the presencea whole [68]. The last measurement (RC) might have
of diabetes mellitus affects peritoneal transport charac-been influenced by the preceding peritonitis episode.
teristics. Data on this issue are equivocal. Nolph andThe persistently low dialysate CA 125 concentrations
colleagues reported lower peritoneal urea and creatininesuggest a small mesothelial cell mass. The incidence of
clearance values in a patient with advanced diabetesmicrobial peritonitis was only one episode per 30 months
during intermittent peritoneal dialysis than in a controlprior to the development of ultrafiltration failure. The
group [107]. In contrast, other studies have found nointervals between the first three episodes were 53 and
59 months. This time course clearly illustrates that the effect on peritoneal solute clearances in CAPD patients
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[108–110], or even higher MTACs [111, 112]. The dura- to 20 weeks [119]. We hope to establish morphologic
tion of peritoneal dialysis is the most probable cause of this functional relationships in this model.
discrepancy. Long-term exposure to glucose will induce Dr. Jo¨rg Plum (Priv. Doz. Department of Nephrology
diabetiform alterations in peritoneal tissues, thereby ob- and Rheumatology, Heinrich-Heine University, Duessel-
scuring initial differences in diabetic and nondiabetic dorf, Germany): Long-term CAPD can lead to the devel-
peritoneal membranes. To test this hypothesis, we stud- opment of a large peritoneal surface area. I can imagine
ied 11 diabetic patients and 11 nondiabetic matched con- this is a good thing to have, because it allows high solute
trols during the first six months of peritoneal dialysis. clearances, which make it easy to reach adequacy targets
The only difference in peritoneal transport between the such as those formulated on the basis of Kt/Vurea.
two groups was the lower transcapillary ultrafiltration Dr. Krediet: Peritoneal solute clearances depend on
rate in the diabetic patients [113]. This difference was the peritoneal surface area and on the drained volume.
absent after one year of CAPD. The results support our For small molecules such as urea, the drained volume is
hypothesis but will have to be confirmed in larger series. the major determinant; for middle molecules such as
Dr. Madias: Does the mode of peritoneal dialysis b2-microglobulin, the surface area is more important than
influence the propensity of patients to develop peritoneal the drained volume. Patients with a large surface area
sclerosis? have low ultrafiltration rates, because glucose absorption
Dr. Krediet: This is unknown, as no separate analysis is high, and the osmotic gradient dissipates rapidly. Con-
has been done on patients starting peritoneal dialysis sequently, these patients can even have low values of
with one of the modalities of automated peritoneal dial- Kt/Vurea. The situation is different when macromolecules
ysis (APD) and continuing this for a long time. Most are used as osmotic agents, such as the glucose polymer
adult patients start with CAPD and switch to APD when icodextrin; diffusion across the peritoneal membrane can
clinical problems, for example, ultrafiltration failure, are be decreased due to their size. Higher ultrafiltration rates
present. From a theoretical point of view, APD with are achieved with icodextrin-based solutions when the
frequent, short hypertonic exchanges will increase the peritoneal surface area is enlarged, as is the case during
exposure of the peritoneum to acid dialysate with high peritonitis [120] and during intraperitoneal administra-
glucose concentrations. This adversity might be counter- tion of nitroprusside [121]. Recent studies have shown
balanced by the lower incidence of infectious peritonitis that patients with a large vascular surface area have an
reported in APD patients [114], but the importance of increased mortality risk [122, 123], possibly because of
this is not known, as data from long-term studies in APD chronic overhydration [124].
are not available to the best of my knowledge. Of our Dr. Plum: Did you also study markers secreted by
own patients with peritoneal sclerosis, only the patient
endothelial cells? This might be relevant because perito-
described in this forum had been treated with CCPD
neal transport mainly depends on the vascular part offrom early on.
the peritoneal membrane.Dr. Madias: Are good animal models available for
Dr. Krediet: We studied the presence of von Wille-studying the membrane failure? If so, what lessons have
brand factor in peritoneal effluent. This protein with awe learned?
very high molecular weight is synthesized by endothelialDr. Krediet: Longitudinal animal models are required
cells. Interestingly, high plasma concentrations haveto study the development of peritoneal membrane fail-
been described in patients with diabetic nephropathyure. In the ideal situation, such models should be in
[125]. We found somewhat higher dialysate concentra-uremic animals and allow the establishment of morpho-
tions of von Willebrand factor in stable CAPD patientslogic–functional relationships. Professor Lameire from
than could be explained by transport from the circula-Belgium has developed a uremic rat model [115]. A
tion. This suggests local release of this protein duringnonuremic longitudinal model in rabbits, allowing peri-
peritoneal dialysis. However, we have not been able totoneal dialysis for four weeks, has been described by
relate the measured concentrations to anything else. AShambye et al [116] and was used for biocompatibility
possible explanation could be that von Willebrand factorstudies [117]. Parameters used in this model were the
is secreted mainly into the capillary lumen instead of theclinical condition of the animals and postmortem exami-
peritoneal interstitium.nation of peritoneal tissues, especially focusing on the
Dr. Detlef O. Schlo¨ndorff (Medizinische Poliklinik,mesothelium. We modified this model for peritoneal
Mu¨nich, Germany): You showed an increase in vesseltransport studies, mainly aimed at pharmacologic inter-
density and also a decrease in aquaporin-mediated waterventions [118]. Gotloib et al used a longitudinal nonure-
transport. I would have expected an increase in the lattermic model of daily intraperitoneal injections of dialysis
due to the larger number of vessels. Could the fibroticfluids in rats and mice and focused on the state of the
alterations that increase the distance from the capillariesmesothelium [83, 84]. We are currently developing a
longitudinal model in the rat for peritoneal dialysis up to the dialysate be important by causing an unstirred
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layer effect that could lead to a decreased diffusional Dr. Krediet: The very high dialysate CA 125 concen-
trations that are present during peritonitis are also indic-water permeability?
Dr. Krediet: The paradox you mentioned between ative of mesothelial cell damage [29]. I agree that perito-
neal fibroblasts can contribute to the extremely highan increase in the number of vessels and a decrease in
channel-mediated water transport indeed suggests se- concentrations of various cytokines that are present in
peritoneal effluent during peritonitis [129]. However, Ivere malfunctioning of the channels, probably by glyco-
sylation of these transcellular proteins. It is not known know of no study on the relative importance of mesothe-
lial cells and fibroblasts as sources of cytokine releasewhether the fibrotic acellular rind found in peritoneal
sclerosis is a barrier to transport or whether it could cause in peritoneal dialysis.
Prof. Jo H.M. Berden (Professor of Nephrology, Divi-an unstirred layer effect. The marked ultrafiltration that
can be obtained using icodextrin-based solution in these sion of Nephrology, University Hospital, Nijmegen, The
Netherlands): You made the comparison with diabeticpatients suggests no decrease in the diffusional water
permeability. microangiopathy. In diabetic nephropathy, beneficial re-
sults have been obtained with angiotensin-converting en-Dr. Thomas H. Ittel (Associate Professor of Medicine,
Department of Internal Medicine, Rheinisch-Westfalische zyme (ACE) inhibitors, both in experimental animals
and in patients. These effects are partly due to correctionTechnische Hochschule, Aachen, Germany): What is
known about the regulation of aquaporin-1 during perito- of hemodynamic abnormalities, but blockade of the
growth factor activity of angiotensin II for different typesneal dialysis, and are cytokines involved in this regulation?
Dr. Krediet: Aquaporin-1, the major water channel of extracellular matrix components might be even more
important. Are you aware of any beneficial effects ofof the erythrocyte plasma membrane, is heavily ex-
pressed at sites of rapid water transport in the kidney and ACE inhibitors in preserving the integrity of the perito-
neal membrane?also in epithelia and endothelia thought to be involved in
water transport. Unlike aquaporin-2, it is not regulated Dr. Krediet: Only short-term experiments have been
done with ACE inhibitors in peritoneal dialysis. Enala-by vasopressin or by water restriction [126]. I know of
no evidence indicating that cytokines are involved in the pril in a dose of 5–10 mg/day decreased blood pressure
but had no effect on peritoneal transport [130]. In aregulation of aquaporins. Intraperitoneal administration
of the aquaporin-1 inhibitor mercury chloride during peri- study using 40 mg/day of enalapril, peritoneal clearances
of creatinine and b2-microglobulin increased [131]. Atoneal dialysis in rats inhibited aquaporin-1, as shown by
a decreased water flow and sodium sieving [127]. clinical study on the possible protective effects of ACE
inhibitors in peritoneal dialysis patients is an interestingDr. Ittel: The formation of advanced glycosylation
end products takes time. For that reason, wouldn’t pa- possibility but would require the inclusion of a large num-
ber of patients and a long follow-up. A study in our long-tients receive more benefit from discontinuous dialysis
regimens, such as daily ambulatory peritoneal dialysis term rat model probably would be easier to perform.
Dr. Berden: Nonanticoagulant heparinoids can re-or nightly intermittent peritoneal dialysis?
Dr. Krediet: Such an approach indeed would reduce duce albuminuria [132, 133] and interact with the deposi-
tion of several extracellular matrix components in dia-the exposure to glucose for 30% to 50% of the day, but it
would have unfavorable effects on the removal of solutes. betic nephropathy [134]. What is known about these
compounds in peritoneal dialysis?Discontinuous dialysis regimens would lead to underdial-
ysis in patients who do not have residual renal function. Dr. Krediet: Baggio’s group in Italy reported the ef-
fects of intraperitoneally administered sulodexide (80%I think that peritoneal glycosylation should be prevented
by the development of better dialysis solutions. low-molecular-weight heparin and 20% dermatan sul-
fate) given daily in CAPD patients over 30 days [135].Dr. Achim Jo¨rres (Nephrology and Intensive Care
Medicine, Virchow-Klinikum, Berlin, Germany): You de- The D/P ratios of urea and creatinine increased, but
peritoneal protein loss decreased. This result suggestslineated the crucial role of the peritoneal mesothelium
in the initiation and control of peritoneal host defense, an increase in vascular surface area in combination with
decreased transport of serum proteins. The albuminuria-but you made no mention of the potential role of the
interstitium. We have shown in the past that peritoneal lowering effect of heparinoids in diabetic nephropathy
has been ascribed to an effect on the glomerular fixedfibroblasts are potent producers of pro- and anti-inflam-
matory cytokines and prostaglandins [128]. This could negative charge [136]. This effect raises the question of
the importance of a charge selectivity in the peritoneum.be especially important during acute peritonitis, because
the inflammation causes serious mesothelial cell damage. Using ruthenium-red staining, fixed negative charges
have been described on the cell surface of endotheliumConsequently, peritoneal fibroblasts might be the pri-
mary cells in the latter part of the inflammatory process, and mesothelium of animals not treated with peritoneal
dialysis, as well as on their basement membranes [137,when down-regulation of the proinflammatory agents
occurs. 138]. However, we have been unable to find any evidence
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for charge selectivity in the transport of macromolecules high compared to the Australian experience, in which a
in CAPD patients. We compared peritoneal clearances mean annual incidence of 4.2 per 1,000 patient years was
of neutral dextran fractions with those of charged pro- reported for the period between 1990 and 1994 [89].
teins with similar Einstein-Stokes radii [139] and com- Dr. Jack F. Wetzels (Division of Nephrology, Univer-
pared the clearances of IgG subclasses [140]. We also sity Hospital, Nijmegen): What happens with the alter-
studied clearances of other proteins with comparable ations in the peritoneal membrane after renal trans-
molecular weights but different isoelectric points, such plantation? Does the process improve or progress, and
as lactate dehydrogenase isoenzymes and amylase, either what is the contribution of the type of immunosuppres-
originating from the pancreas or from salivary glands sive therapy? Is it possible that cyclosporine treatment
[141]. For none of the investigated proteins was any further damages the peritoneal membrane by its fibro-
evidence found for charge selectivity. One of the expla- genic effect and vasoconstrictive actions? The reason for
nations for this discrepancy again could be exposure of my question is that we observed a patient who developed
the peritoneal membrane to glucose. This exposure could peritoneal sclerosis between three and six months after
lead to impairment of heparan sulfate metabolism [142] transplantation.
with loss of charge selectivity, as is the case in diabetic Dr. Krediet: Peritoneal sclerosis developed after dis-
nephropathy [143]. continuation of peritoneal dialysis in two of the nine
Dr. Peter Gross (Nephrologie, Universita¨tsklinikum patients reported by Rottembourg et al [74] and in 9 of 62
CG Carus, Dresden, Germany): Is it known whether Japanese patients after previous transfer to hemodialysis
aquaporin-1 can be subject to nonenzymatic glycosyla- [90]. It has been described in patients after renal trans-
tion, and do you know how the density of aquaporin-1 plantation [145]. Peritoneal sclerosis also occurred in 4
in peritoneal endothelial cells compares with its density of 16 patients in our own series [61]. In 2 of 16, the clinical
on the red blood cell membrane? symptoms appeared after transfer to hemodialysis. It
Dr. Krediet: Aquaporin-1 exists as a tetramer, proba- follows from the data that the sclerosing process can
bly composed of three nonglycosylated subunits and one proceed even after discontinuation of exposure to the
bearing a large polylactosaminoglycan [144]. I see no noxious agents.
reason why the other subunits could not be glycosylated This raises a question about the role of immunosup-
in a situation of chronic exposure to extremely high glu- pressive treatment. A dramatic improvement after corti-
cose concentrations. I do not know of data comparing costeroids and azathioprine has been described in iso-
the density of aquaporin-1, or the osmotic water perme- lated cases [146] and in 5 of the 17 patients with
ability, between red blood cells and peritoneal microves- chlorhexidine-induced peritoneal sclerosis from Glas-
sels during peritoneal dialysis.
gow [147]. Five of the 54 patients from Australia were
Prof. Jutta Passlick-Deetjen (Fresenius Medical
treated with immunosuppression; in two of them, therapy
Care, Oberursel, Germany): How do you define perito-
led to improvement of the symptoms. We treated fiveneal sclerosis? What is the percentage of patients with
of our patients with immunosuppression but could notperitoneal sclerosis in your population, and is this per-
demonstrate a convincing beneficial effect. The variablecentage high compared to other studies?
response to immunosuppression might be caused by dif-Dr. Krediet: We divided our patients with possible
ferences in the medication. Although not precisely statedperitoneal sclerosis into three categories [61]. Category
in all papers, I have the impression that most authorsI (definite peritoneal sclerosis) was defined as the pres-
reporting a favorable effect used only steroids and aza-ence of two clinical symptoms, either abdominal compli-
thioprine, while those who were unable to demonstratecations (bowel obstruction, blood-stained effluent, se-
an effect used cyclosporine A in their immunosuppres-vere ascites after discontinuation of peritoneal dialysis)
sive treatment, because of the presence of a renal trans-or ultrafiltration failure, in combination with confirma-
plant. This hypothesis on a possible contributing role oftion of the diagnosis by macroscopic examination of the
cyclosporine A should be tested in further studies.abdominal viscera either at laparotomy or autopsy. Ap-
Dr. Wetzels: Is it feasible to perform a peritonealproximately 62% of our patients fulfilled these criteria.
equilibration test three to four months after transplanta-Category II (19% of our cases; probable peritoneal scle-
tion, just before removing the catheter?rosis) was defined as the presence of only one clinical
Dr. Krediet: We tried this some years ago but foundsymptom or no macroscopic confirmation. In category
that the catheter was blocked in most patients. To per-III (19% of the cases), the diagnosis was doubtful be-
form peritoneal equilibration tests after transplantation,cause no definite macroscopic diagnosis was made and
the catheter should probably be flushed daily. Such aclinical features were not convincing. Taking only cate-
procedure carries the risk of introducing microorganismsgories I and II, the incidence was 3.5 per 1,000 patient
and is therefore not acceptable.years. It increased to 4.6 per 1,000 patient years when
category III was included. This number is not unusually Dr. Madias: What are the similarities and differences
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in peritoneal membrane characteristics of the reversible have low values already during the first few years of
CAPD [31]. The reason for this is not clear. Possibly theultrafiltration loss that occurs during acute infectious
peritonitis and the irreversible ultrafiltration failure of mesothelial cells of these patients just express less CA
125 than do those of other patients. However, a decreaseperitoneal sclerosis?
Dr. Krediet: The transport of low-molecular-weight in dialysate CA 125 strongly suggests loss of mesothelial
cell mass.solutes is increased during acute peritonitis [148] and in
most patients with peritoneal sclerosis [60, 61], although Prof. R. Bernd Sterzel (Professor of Medicine, Uni-
versity of Erlangen-Nu¨rnberg, Germany): What is thelow transport rates have been reported [60, 149]. I know
of no data comparing the sieving of sodium in acute perito- validity of CT scanning for the diagnosis of peritoneal
sclerosis, and is there a better diagnostic approach?nitis and in peritoneal sclerosis. A difference is present
between infectious peritonitis and long-term peritoneal Dr. Krediet: I do not think that CT scanning is very
useful for an early diagnosis of peritoneal sclerosis. In 6dialysis in the intrinsic permeability for macromolecules:
The RC is decreased in the acute phase of peritonitis of the 10 patients from our series with category I perito-
neal sclerosis [61], CT scans showed severe alterations.[129] but increased in long-term peritoneal dialysis [63].
Because peritoneal sclerosis is a complication of long- Minimal alterations were found in three patients, and in
one patient, no CT scan had been done. In the threeterm peritoneal dialysis, we also investigated the RC in
this patient group, but the data available were too small patients in Category II, CT scanning showed either no,
minimal, or severe changes. Among the three patientsto draw conclusions. Although the interpretation of this
disparity is speculative, the decreased RC in acute perito- with a doubtful clinical diagnosis (Category III), two
had minimal alterations, but one patient showed severenitis might be due to an increase in the large pore size
possibly caused by inflammatory mediators. In contrast, abnormalities. In only two patients were CT scans so
convincing that no laparotomy had been done to confirmthe increased RC in long-term peritoneal dialysis might
reflect increased size selectivity of the peritoneal mem- the diagnosis. Therefore, a negative CT scan does not
exclude the diagnosis of peritoneal sclerosis, but onebrane caused by interstitial fibrosis. Loss of mesothelial
cells occurs both during acute peritonitis and in perito- with severe abnormalities in combination with transport
abnormalities makes the diagnosis very likely. This clini-neal sclerosis. Acute loss of mesothelial cells is reflected
in increased dialysate CA 125 concentrations [29], but cal scenario can be a reason to refrain from a diagnostic
laparotomy because of the high morbidity of this opera-this change is followed by a return to normal values [29,
150]. In contrast, most patients with peritoneal sclerosis tion in peritoneal sclerosis. Reviewing all CT scans with
our radiologist made us conclude that this investigationhave low dialysate CA 125 concentrations [69].
Dr. H. Messner (Kuratorium fu¨r Dialyze, Wuppertal, should preferably be done with oral contrast in the bowel
and the peritoneal cavity filled with dialysis fluid. ThisGermany): Do the results of the peritoneal equilibration
test at the start of dialysis identify patients who are at facilitates interpretation of the images. Some studies
have described the use of ultrasound and of the colonrisk for ultrafiltration loss and peritoneal sclerosis?
Dr. Krediet: That question is difficult to answer. Some transit time as assessed after a barium meal [151], but
we did not find these investigations to contribute to thepatients have high solute transport rates in the first few
weeks of peritoneal dialysis. These high rates often de- diagnosis, except in patients in whom only a localized
bowel stenosis was present.crease during the following weeks, and a baseline level
is usually reached after two to three months [64]. Those Dr. Sterzel: What was the reason for acute pancreatitis
in your patient? Could alcohol abuse have been involved?with persistently high solute transport rates have a lower
patient and technique survival, probably because of com- Dr. Krediet: Alcohol abuse is unlikely in this patient,
first because he is a Muslim and second because he devel-plications of chronic overhydration [122–124]. Conse-
quently, a large number of these patients will have dis- oped pancreatitis when he was already in the hospital
and closely supervised. Peritonitis can be complicatedcontinued peritoneal dialysis before peritoneal sclerosis
develops. However, our data have shown that extensive by acute pancreatitis [101]. In our study of 24 episodes of
acute pancreatitis in CAPD patients, we found positiveuse of 3.86% glucose dialysate, either due to a rapid
dissipation of the osmotic gradient, absence of residual dialysate cultures in five, mainly with skin flora [102].
This finding raises the question of whether peritonitisrenal function, or excessive fluid intake, is likely to be
a risk factor. was the cause or the consequence of pancreatitis [101].
It may be that the proteolytic enzymes released duringDr. W. Pommer (Humbolt Hospital, Berlin, Germany):
What is the potential impact of CA 125 in clinical medi- pancreatitis interfere with local host defense mechanisms.
However, the time relationship between peritonitis andcine? Does it predict peritoneal membrane failure?
Dr. Krediet: The interpretation of a single low dialy- pancreatitis in our patient is more suggestive of pancre-
atitis as a complication of peritonitis. The combinationsate CA 125 concentration is difficult. Some patients can
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